期刊文献+

Pioneer of prostate cancer: past, present and the future of FOXA1 被引量:14

原文传递
导出
摘要 Prostate cancer is the most commonly diagnosed noncutaneous cancers in North American men.While androgen deprivation has remained as the cornerstone of prostate cancer treatment,resistance ensues leading to lethal disease.Forkhead box A1(FOXA1)encodes a pioneer factor that induces open chromatin conformation to allow the binding of other transcription factors.Through direct interactions with the Androgen Receptor(AR),FOXA1 helps to shape AR signaling that drives the growth and survival of normal prostate and prostate cancer cells.FOXA1 also possesses an AR-independent role of regulating epithelial-to-mesenchymal transition(EMT).In prostate cancer,mutations converge onto the coding sequence and c/s-regulatory elements(CREs)of FOXA1,leading to functional alterations.In addition,FOXA1 activity in prostate cancer can be modulated post-translationally through various mechanisms such as LSD1-mediated protein demethylation.In this review,we describe the latest discoveries related to the function and regulation of FOXA1 in prostate cancer,pointing to their relevance to guide future clinical interventions.
出处 《Protein & Cell》 SCIE CAS CSCD 2021年第1期29-38,共10页 蛋白质与细胞(英文版)
  • 相关文献

参考文献1

共引文献3

同被引文献58

引证文献14

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部